Maria Luisa Sulis

Trials

Studies that name Maria Luisa Sulis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:08 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07012044 · A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  National Cancer Institute (NCI) · recruiting · Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT05146739 · Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

  National Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application
  UM1CA228823 · NCI · COG RESEARCH FOUNDATION, LLC · PI Elizabeth Fox · fiscal years 2018 to 2026
  Named on NCT07012044, NCT05146739